Skip to main content
. 2021 Dec 7;15(1):101302. doi: 10.1016/j.tranon.2021.101302

Fig. 8.

Fig. 8

Inhibitory effect of NM on endocrine-resistant ERPBC in xenograft models and a model to summarize the results. (A) Eight-week-old female SCID mice were inoculated with MCF7-TemR and MCF7-FulR cells orthotopically. On Day 32, mice were injected with saline and nafamostat mesylate (30 mg/kg) three times a week, intraperitoneally. (B) Nafamostat mesylate significantly decreased tumor growth. The tumor sizes were measured at Day 56. The upper tumors are the control groups and the lower are nafamostat mesylate treatment. (C) Tumor progression was time-dependent. (D) The body weights were not significantly different between the control and nafamostat mesylate treatment groups. (E) Nafamostat mesylate significantly reduced expressions of CDK4 and CDK6 by immunohistochemistry stain analysis. Scale bars represented 200 mm. (F) Decreased nucleus staining in the Nafamostat mesylate-treated mice. There is a statistical significance between control and nafamostat mesylate-treated mice (*P < 0.001). Six mice were used for each group. (G) A model to summarize the results of this report.